de2e0c63-0c2d-43af-a006-7d84557a1c3c
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 77
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- HEDGEHOG_SIGNALING+0.400
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.270
- INTERFERON_ALPHA_RESPONSE+0.250
- UV_RESPONSE_DN+0.250
- MYOGENESIS+0.200
- IL6_JAK_STAT3_SIGNALING+0.190
- INTERFERON_GAMMA_RESPONSE+0.180
- WNT_BETA_CATENIN_SIGNALING+0.150
- ANGIOGENESIS+0.120
- APICAL_JUNCTION+0.100
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.590
- MYC_TARGETS_V1-0.450
- FATTY_ACID_METABOLISM-0.410
- GLYCOLYSIS-0.400
- MTORC1_SIGNALING-0.370
- ADIPOGENESIS-0.360
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.360
- PEROXISOME-0.330
- DNA_REPAIR-0.310
- P53_PATHWAY-0.310
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | GSM5359411 | — | — | 0.904 |
| 2 | C3N-03890 | — | cohortA1 | 0.877 |
| 3 | MNG690 | — | — | 0.876 |
| 4 | SRR6013599 | — | cohortMD2 | 0.870 |
| 5 | 3383d8e1-d61d-4346-a589-007ad2829e36 | — | — | 0.867 |
| 6 | 44eb0b78-9761-4131-b831-85e765a24e6b | — | — | 0.861 |
| 7 | 895018d4-b355-4339-8c60-186478ae6551 | — | — | 0.852 |
| 8 | AUR-AG12-TTP1-A-1-0-R-A741-41 | — | A | 0.847 |
| 9 | TCGA-DK-AA6S-01A-21R-A39I-07 | — | — | 0.846 |
| 10 | TCGA-QK-A8Z9-01B-11R-A39I-07 | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.270 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.250 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.250 | Inavolisib | — uncovered |
| MYOGENESIS | 0.200 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.190 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.180 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.150 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.120 | Remibrutinib | — uncovered |
| APICAL_JUNCTION | 0.100 | Inavolisib | — uncovered |
| COAGULATION | 0.080 | Binimetinib | — uncovered |
| KRAS_SIGNALING_DN | 0.070 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.070 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.070 | Cobimetinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.060 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.020 | Temsirolimus | — uncovered |
| TGF_BETA_SIGNALING | 0.010 | Inavolisib | — uncovered |